Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,151 recruiting studies in this area right now.
By phase
- Not applicable9,506
- Phase 24,400
- Phase 12,662
- Phase 1/Phase 21,649
- Phase 31,391
- Phase 2/Phase 3283
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer647
- Cancer634
- Colorectal Cancer480
- Lung Cancer416
- Ovarian Cancer336
- Multiple Myeloma328
- Pancreatic Cancer288
- Gastric Cancer283
- Acute Myeloid Leukemia279
- Hepatocellular Carcinoma256
- Solid Tumor245
- Advanced Solid Tumor235
- Head and Neck Cancer225
- Cervical Cancer223
- Endometrial Cancer207
- Advanced Solid Tumors201
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center288
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center141
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences140
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,408
- Texas635
- Arizona512
- Florida434
- Alabama427
- New York405
- Massachusetts342
- Maryland330
- New Jersey269
- Pennsylvania234
Recruiting studies20,151 total
- NCT07602777RecruitingPhase 1/Phase 2
Testing Risvutatug Rezetecan for Advanced Bone and Soft Tissue Sarcomas
This study tests a new cancer drug called risvutatug rezetecan for people with advanced sarcomas (bone or soft tissue cancers) that have stopped responding to prior treatments. The drug works by delivering a cancer-killing agent directly to tumor cells.
West Valley City, UtahAges Any age - NCT07603479RecruitingPhase 1
Testing JL19001 for Advanced Cancers and Lymphoma
This is an early-stage study testing a new drug called JL19001, alone or combined with standard treatments, for people with advanced solid tumors (like melanoma, lung cancer, or kidney cancer) or relapsed/refractory B-cell lymphoma who have exhausted standard options. The trial aims to find the safest dose and understand how well the drug works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07602088Recruiting
Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
BucharestAges 18 years+ - NCT07600554RecruitingPhase 1
Imaging Study for Prostate Cancer Detection
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
Bergamo, BergamoAges 18 years+ - NCT07602842RecruitingPhase 1/Phase 2
Testing IDP-001 for advanced solid tumors
This early-stage trial tests a new drug called IDP-001 in people with advanced cancers that have spread or cannot be surgically removed. The study aims to find the right dose and see how well the drug works against various solid tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT07601243RecruitingPhase 1
GS-2426 for advanced solid tumors with MTAP deficiency
This study tests a new drug called GS-2426 for people with advanced solid tumors that have a specific genetic change called MTAP deficiency. It may be an option if other treatments have stopped working or are not available.
Boston, MassachusettsAges 18 years+ - NCT07600476RecruitingPhase 1
Safety Study of KUP-101A in Advanced Solid Tumors
This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.
Munich, BavariaAges 18 years+ - NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT07602855RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This study tests a new combination of two investigational drugs for people with advanced solid tumors, especially lung cancers. The goal is to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07595237RecruitingEarly Phase 1
Radioactive treatment for advanced solid tumors with Claudin18.2
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07597772RecruitingEarly Phase 1
Testing SNA014 for Pancreatic Cancer
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07601334RecruitingPhase 1
Testing HF50 safety in advanced solid tumors
This Phase 1 trial tests a new drug called HF50 in people with advanced cancers that have spread or cannot be surgically removed. The goal is to see if HF50 is safe and whether it helps shrink tumors in patients whose cancer has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07597993Recruiting
Real-world study of Trastuzumab Deruxtecan for advanced breast cancer
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
MuscatAges 18 years+ - NCT06716164RecruitingEarly Phase 1
Experimental car-t cell therapy for relapsed b-cell lymphoma
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Hangzhou, ZhejiangAges 19–70 - NCT07601178RecruitingPhase 2
Immunotherapy and targeted drugs for advanced triple-negative breast cancer
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07595770RecruitingPhase 2
New immunotherapy combined with chemotherapy and radiation for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07595224Recruiting
Post-surgery radiation therapy for cervical and uterine cancer
This trial tests a shorter, focused radiation treatment to the pelvis after surgery for cervical or uterine cancer. It aims to reduce the chance of cancer coming back in patients whose doctors recommend additional radiation therapy after their surgery.
Bangkok, BangkokAges 18 years+ - NCT07595666Enrolling by invitation
New PET scanner versus standard PET for head and neck imaging
This study compares a newer PET/CT scanner (called NeuroEXPLORER) with standard PET/CT scanners for imaging the head and neck region. The goal is to see if the new scanner provides better or clearer images to help diagnose conditions.
Leuven, Vlaams-BrabantAges 4 weeks+ - NCT07602010Recruiting
Comparing CT and MRI scans for bladder cancer staging
This trial compares two imaging methods—CT and MRI scans—to see which one better shows how far bladder cancer has spread before surgery. If you have newly diagnosed bladder cancer and are planning surgery, this study may help doctors choose the best imaging for your care.
OsloAges 18 years+ - NCT07602049RecruitingPhase 2
Freezing Plus Immunotherapy for Advanced Soft Tissue Sarcoma
This trial combines cryoablation (a freezing technique to destroy tumors) with camrelizumab (an immunotherapy drug that helps your immune system fight cancer) for patients with advanced soft tissue sarcoma that hasn't responded to standard treatments. The goal is to see if this combination works better than current options.
Guangzhou, GuangdongAges 14–70 - NCT07601464Recruiting
MicroRNA Changes in Liver Cancer Treated with Heat
This study examines how certain molecules in your blood and tumor tissue change when liver cancer is treated with heat ablation (a procedure that destroys tumors using heat). Understanding these changes may help doctors better predict treatment success in the future.
Bologna, Emilia-RomagnaAges 18–64 - NCT07599371RecruitingPhase 1/Phase 2
Ivoximab and temozolomide for recurring brain tumors
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Zhengzhou, HenanAges 18–85 - NCT07600801Recruiting
Lung Cancer Screening for People With Family History
This study looks at how to best screen people for lung cancer who have close relatives with a history of lung cancer. Researchers will use existing CT chest scans (imaging tests) to see if screening can help catch lung cancer early in high-risk families.
Boston, MassachusettsAges 18 years+ - NCT07595172RecruitingPhase 1/Phase 2
New drug combination for advanced pancreatic cancer
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Chengdu, SichuanAges 18–75
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,151 recruiting oncology studies from the U.S. registry right now, out of 30,040 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.